GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

zovaglutide Arm 1

Company
Beijing QL Biopharmaceutical Co.,Ltd
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for zovaglutide Arm 1 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07443059

    A Study of Zovaglutide (ZT002 Injection) in Participants With Impaired Kidney Function and Healthy Participants

    Not yet reported Beijing QL Biopharmaceutical Co.,Ltd 40 participants Est. completion 2027-03-19 3 sites
    Other conditions: Overweight , Obesity
    View official trial listing →
  • Recruiting NCT NCT07550816

    Drug-drug Interaction Study of ZT002 Injection in Overweight and Obese Participants

    Not yet reported Beijing QL Biopharmaceutical Co.,Ltd 60 participants Est. completion 2027-03-26 1 site Stand-alone
    Other conditions: Overweight,Obesity
    View official trial listing →
  • Completed NCT NCT05491421

    A Study of ZT002 in Healthy Participants

    Not yet reported QL Biopharmaceutical Australia Pty Ltd 32 participants Est. completion 2023-04-28 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT06371326

    A Study of ZT002 Injection in Participants With Overweight or Obesity

    Not yet reported Beijing QL Biopharmaceutical Co.,Ltd 28 participants Est. completion 2024-10-17 1 site Stand-alone
    Other conditions: Overweight or Obesity
    View official trial listing →
  • Completed NCT NCT06423872

    A SAD Study of ZT002 Injection in Healthy Participants

    Not yet reported Beijing QL Biopharmaceutical Co.,Ltd 28 participants Est. completion 2023-12-08 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT07020884

    A Study of ZT002 Injection With Subjects With Overweight or Obesity

    Not yet reported Beijing QL Biopharmaceutical Co.,Ltd 303 participants Est. completion 2025-05-29 16 sites Stand-alone
    Other conditions: Overweight or Obesity
    View official trial listing →
  • Completed NCT NCT07065032

    A Study of ZT002 Injection in Adult Chinese Subjects With Type 2 Diabetes Mellitus (T2DM)

    Not yet reported, Not yet reported Beijing QL Biopharmaceutical Co.,Ltd 27 participants Est. completion 2024-08-05 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Active, not recruiting NCT NCT07230119

    A Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1)

    Not yet reported Beijing QL Biopharmaceutical Co.,Ltd 755 participants Est. completion 2027-06-26 45 sites
    Other conditions: Overweight , Obesity
    View official trial listing →
  • Not yet recruiting NCT NCT07697846

    A Study to Investigate the Effects of Zovaglutide (ZT002 Injection) on QTc Interval in Healthy Adults

    Not yet reported Beijing QL Biopharmaceutical Co.,Ltd 40 participants Est. completion 2027-03-24 1 site Stand-alone
    Other conditions: Overweight, Obesity
    View official trial listing →
  • Not yet recruiting NCT NCT07812597

    A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ)

    Not yet reported Beijing QL Biopharmaceutical Co.,Ltd 210 participants Est. completion 2028-03-24 16 sites Stand-alone
    Other conditions: Obesity
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: zovaglutide Arm 1, ZT002, zovaglutide Arm 2

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.